The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy
Abstract
Pharmacological use of ascorbate (vitamin C) enhanced chemosensitivity of ovarian cancer in preclinical models and reduced chemotherapy-associated toxicity in patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A significant number of human studies consistently show that ascorbate treatment improved quality of life for patients with cancer, and in combination therapy, ascorbate protected normal tissues from toxicity caused by chemotherapy114.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [114]
In the citing paper
“A significant number of human studies consistently show that ascorbate treatment improved quality of life for patients with cancer, and in combination therapy, ascorbate protected normal tissues from toxicity caused by chemotherapy114.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [114]
In the citing paper
“This paper shows in its preclinical and clinical studies that high-dose vitamin C can potentially increase the efficacy and reduce the toxicities of certain conventional chemotherapies when used in combination to treat patients with ovarian cancer.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [114]
Citations
Cites
1 retracted
Huang, Q. B., Wu, Y., Tan, H.-L., Ong, C.-N., & Shen, H.-M. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.151 · Cited by 116
RetractedA simple technique for quantitation of low levels of DNA damage in individual cells
Singh, N. P., McCoy, M. T., Tice, R. R., & Schneider, E. L. (1988) · Experimental Cell Research · doi:10.1016/0014-4827(88)90265-0 · Cited by 10,828
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Rapid colorimetric assay for cell growth and survival
Denizot, F., & Lang, R. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90368-6 · Cited by 4,935
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance
Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, K. R., Park, J. B., Lazarev, A., Graumlich, J. F., King, J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3704 · Cited by 1,325
Self-citationChen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506390102 · Cited by 1,075
Self-citationVitamin C pharmacokinetics: Implications for oral and intravenous use
Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Wesley, R. A., & Levine, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00010 · Cited by 992
Self-citationChen, Q., Espey, M. G., Sun, A. Y., Pooput, C., Kirk, K. L., Krishna, M. C., Khosh, D. B., Drisko, J., & Levine, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804226105 · Cited by 854
Self-citationATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS
Alexander, A., Cai, S.-L., Kim, J., Nanez, A., Sahin, M., MacLean, K. H., Inoki, K., Guan, K.-L., Shen, J., Person, M. D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913860107 · Cited by 717
Cited by
Sorted by citations
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
ROS and the DNA damage response in cancer
Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144
“On the other end of the spectrum, due to the diverse effects described above for ROS in activating various DNA damage responses, high ROS is also associated with resistance to chemotherapy [18,136].”
BackgroundAntioxidant and Oxidative Stress: A Mutual Interplay in Age-Related Diseases
Tan, B. L., Norhaizan, M. E., Liew, W.-P.-P., & Rahman, H. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01162 · Cited by 1,221
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913
“xenograft models (37, 38), the mechanism by which vitamin”
BackgroundReactive oxygen species and cancer paradox: To promote or to suppress?
Galadari, S., Rahman, A. U., Pallichankandy, S., & Thayyullathil, F. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.004 · Cited by 918
Metadata
- Authors
- Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q.
- Affiliations
- University of Kansas Medical Center (US)
- National Institutes of Health (US)
- Corresponding author
- Drisko, Jeanne
- Chen, Qi
- Venue
- Science Translational Medicine
- Published
- 2014-02-05
- Volume
- 6
- Issue
- 222
- Pages
- 222ra18-222ra18
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2139847043
- Cited by
- 501
- References
- 57
- Citations by year
- 2026: 23 · 2025: 29 · 2024: 44 · 2023: 55 · 2022: 50 · 2021: 51 · 2020: 42 · 2019: 44 · 2018: 53 · 2017: 38 · 2016: 28 · 2015: 23 · 2014: 21
- FWCI
- 34.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Vitamin C and Antioxidants Research
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- vitamin C, ovarian cancer, chemosensitization, carboplatin, paclitaxel, chemotherapy toxicity, pro-oxidant activity, hydrogen peroxide, DNA damage, ATP depletion, mTOR inhibition, combination therapy, cancer cell death
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Ascorbic Acid, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Synergism, Female, Humans, Infusions, Parenteral, Ovarian Neoplasms, Carboplatin, Cell Death, Paclitaxel, Xenograft Model Antitumor Assays, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
